Histologic studies of intravesical oxybutynin in the rabbit.
Intravesically applied oxybutynin has been reported to have no significant systemic anticholinergic side effects, with excellent efficacy in the treatment of neurogenic bladder dysfunction. Currently, the morphologic effects of intravesical oxybutynin on the local bladder tissue are not well established. It is the purpose of this study to address this issue in an animal model. Thirty-nine New Zealand White female rabbits were catheterized daily and intravesical solutions instilled for as long as 30 days. In part A of the study, the overall histologic effects of intravesical oxybutynin were examined by comparing oxybutynin with saline administration. Part B of this study compared the relative effects of crushed oxybutynin tablets and pure oxybutynin powder. The bladder histology and urine microbiological studies were analyzed in a blinded fashion. We found that the crushed oxybutynin tablets and saline administered intravesically produced similarly mild inflammation in the bladders (p < 0.05). When we compared the crushed oxybutynin tablets and pure oxybutynin powder, however, the crushed tablet group was found to have a mild eosinophilic infiltrate seen in 5 of 9 animals, which was not observed in any of the animals in the other groups (p = 0.029). Qualitative and quantitative analyses of the microbiological findings were not different among the different groups (p > 0.05). Our findings support the clinical use of intravesical oxybutynin as being safe for local tissue. However, consideration should be given to the use of the pure powdered form of oxybutynin, since the crushed oxybutynin tablets may lead to allergic reactions.
Landau
E H
EH
Department of Surgery (Division of Urology), Hospital for Sick Children, Toronto, Ontario, Canada.
Fung
L C
LC
Thorner
P S
PS
Mittelman
M W
MW
Jayanthi
V R
VR
Churchill
B M
BM
McLorie
G A
GA
Steckler
R E
RE
Khoury
A E
AE
D000283:Administration, Intravesical; D000818:Animals; D003556:Cystitis / Q000139:chemically induced; D005260:Female; D008333:Mandelic Acids / Q000008:administration & dosage / Q000494:pharmacology*; D010276:Parasympatholytics / Q000008:administration & dosage / Q000494:pharmacology*; D011208:Powders; D011817:Rabbits; D012965:Sodium Chloride; D013607:Tablets; D001743:Urinary Bladder / Q000187:drug effects* / Q000473:pathology*
D008333:Mandelic Acids; D010276:Parasympatholytics; D011208:Powders; D013607:Tablets; D012965:Sodium Chloride; C005419:oxybutynin